CSO RADIO public
[search 0]
More
Download the App!
show episodes
 
Artwork

1
EU Watchdog Radio

Corporate Europe Observatory and Counter Balance

Unsubscribe
Unsubscribe
Monthly
 
EU Watchdog Radio is a bi-weekly podcast launched by two Brussels NGO's: Counter Balance and Corporate Europe Observatory. In each episode, we dive deeper into topics that relate to our activities in Brussels. Whether it be steps to increase transparency of lobbies in the EU or how to tackle public investment in a way that works for everyone. We explore it all, right here at EU Watchdog Radio!
  continue reading
 
Welcome to BIOTECH NATION !!! With understandable interviews requiring no background in science, BTN attracts a wide global audience. From everyday people looking for hope in treatments in development, to bioentrepreneurs interested in the experience of their fellow travelers, to venture capitalists looking for possibilities in cutting-edge breakthroughs, to scientists simply interested in the work of others, BioTech Nation is the voice of human endeavor, driving science to new realities for ...
  continue reading
 
Artwork

1
Knight & Day

Too good for Radio Four. Too cool for Channel Four.

Unsubscribe
Unsubscribe
Monthly
 
Knight & Day follows the adventures of newly qualified CSO, Gary Knight, and his new partner, Gareth Day, on their journey for justice. It's up to them to save the Day - and the Knight.
  continue reading
 
Loading …
show series
 
This week on Biotech Nation, Dr. Neil Kumar, founder and CEO of BridgeBio Pharma. Dr. Kumar emphasizes that genetic diseases, particularly Mendelian diseases caused by single gene mutations, are solvable due to advancements in genetic measurement and understanding. He discusses BridgeBio Pharma's innovative corporate structure, which consists of mu…
  continue reading
 
As it prepares to usher in a new era of austerity, the EU is rife with declarations of increased militarisation, coupled with measures to significantly increase European arms spending and strengthen the Union's military capabilities. In this episode, Laëtitia Sédou of ENAAT looks at the impact of skyrocketing military spending, the powerful influen…
  continue reading
 
What’s next after Ozempic and Wegovy and the like? How about a drug in development which releases all the relevant hormones, and not just GLP-1. And doesn’t require injecting. Dr. Steffen-Sebastian Bolz from Aphaia (ah-phi-ah) Pharma explains their approach, currently in Phase 2.By Moira Gunn
  continue reading
 
This week on BioTech Nation, Dr. Sam Blackman, Founder and Head of Research and Development from Day One Biopharmaceuticals, shares the story behind the FDA approval of a groundbreaking drug for the most common childhood brain cancer. He talks about their innovative approach to starting a biopharma company and how it led to a newly FDA approved dru…
  continue reading
 
This week we have a best of rerun with Dr. Mark Sumeray from Amolyt Pharma. Dr. Sumeray talks about their innovative approach to treating hormonal conditions. We’ll talk about two – when your parathyroid has been injured or removed, often during thyroid surgery, and another – when the pituitary starts overproducing growth hormone.…
  continue reading
 
This week Dr. Daniel Kraft, Tech Nation Health Chief Correspondent, discusses advanced health tech. Dr. Kraft highlights his use of wearables like the Apple Watch, Oura ring, and non-invasive blood pressure monitors. He also introduces "otherables," which track health without being worn, using devices like cameras and modified WiFi. These technolog…
  continue reading
 
During the current and almost over EU legislature, the rise of far-right forces has come hand in hand with the stigmatisation, harassment, and violence against women and LGBTQI+ people.In this episode, Corporate Europe Observatory researcher and campaigner Kenneth Haar unveils the link between ultraconservative US foundations and right-wing forces …
  continue reading
 
This week on BioTech Nation, Dr. Moira Gunn and Dr. Daniel Kraft discuss how robotics, AI, and virtual reality are transforming surgery. These technologies make procedures less invasive and improve training and outcomes worldwide. Future advancements may include tiny robots performing internal procedures. Security is crucial to prevent hacking of m…
  continue reading
 
Dr. John Scarlett, President and CEO of Geron Corporation talks about their drug Imetelstat for myelodysplastic syndrome (MDS). MDS patients often require frequent blood transfusions, impacting their quality of life. Imetelstat, a telomerase inhibitor, aims to reduce transfusion dependence by targeting cancer cells in the bone marrow. Phase three t…
  continue reading
 
Dr. Daniel Kraft, Tech Nation Health Chief Correspondent discusses the gap between medical innovation and its adoption into standard practice. He highlights that it typically takes 17 years for a medical discovery to become common practice, but big data and AI could accelerate this. He emphasizes the importance of sharing medical data and initiativ…
  continue reading
 
This week, Dr. Steve Quake from the Chan Zuckerberg Initiative about their goal to tackle all human diseases in the next century. We discuss CZI's innovative approach, including building Biohubs and funding collaborative research. Dr. Quake explains the importance of something called The Virtual Cell project, aiming to use AI to model every human c…
  continue reading
 
This week on Biotech Nation, I speak with Dr. Neal Kassell about focused ultrasound technology. We discuss its noninvasive approach, its diverse applications in treating various medical conditions, and its potential to revolutionize treatments for diseases like Alzheimer's, Parkinson's, and cancer. Dr. Kassell also shares insights into ongoing clin…
  continue reading
 
This week on BioTech Nation, we explore new efforts in treating cancer with Dr. Sean Bohen, President and CEO of Olema Oncology. We discuss progress in treating breast cancer, particularly ER+/HER2- breast cancer, which accounts for 70% of diagnoses this year. They examine the biology behind these cancers and how Olema's lead compound, palazestrant…
  continue reading
 
In a milestone win for civil society, the EU will withdraw from the climate-wrecking Energy Charter Treaty (or ECT). The ECT was designed in the 1990s to favour industry’s interests, and was a powerful weapon to obstruct the kind of phaseout of fossil fuels needed to avoid catastrophic climate change. It should never have existed in the first place…
  continue reading
 
This week - Dr. Sanjay Shukla, CEO of Atyr Pharma, discusses the revolutionary potential of mRNA technology in creating new medicines. They explore Atyr's pioneering approach to leveraging tRNA fragments for treating pulmonary sarcoidosis and other organ-specific conditions, aiming to improve patient outcomes while minimizing reliance on convention…
  continue reading
 
For the first time in seventeen years, the European Gas Conference was cancelled—or, at least, postponed. However, this did not stop CEO from travelling all the way to Vienna to meet with climate activists and campaigners at the People’s Summit, the counter-summit of the Gas Conference.This episode was recorded live in the capital city of Austria. …
  continue reading
 
Dr. Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, discusses the revolutionary approach of detecting cancer at its earliest stages through circulating tumor DNA (ctDNA) tests. Highlighting their innovative treatment method, which aims to train the body's immune cells to recognize and destroy cancer cells, the episode explores the po…
  continue reading
 
In this week's episode, Dr. Moira Gunn interviews Dr. Chris Pirie from HDT Bio about their novel approach to cancer prevention through vaccines. They discuss leveraging mRNA technology to target specific tumor mutations and prime the immune system to recognize and eliminate cancer cells. Dr. Pirie highlights ongoing efforts to develop vaccines for …
  continue reading
 
This week I speak with Dr. Robert Ang from Vor Biopharma about their innovative approach to treating acute myeloid leukemia (AML). AML is a type of blood cancer that affects the bone marrow, leading to the overgrowth of cancerous cells. Dr. Ang explains that traditional treatments, such as chemotherapy and stem cell transplants, have limitations an…
  continue reading
 
In this week's episode of BioTech Nation, Dr. David Bearss, President and CEO of Halia Therapeutics, discusses inflammation and its reduction over a lifetime and in response to various incidents. He unveils the inflammasome, a recently discovered protein complex critical in regulating inflammatory responses and its potential in treating chronic dis…
  continue reading
 
Tech Nation Health, Chief Correspondent Dr. Daniel Kraft discusses the concept of "food as medicine." Dr. Kraft emphasizes the evolving understanding of nutrition and its profound impact on health, advocating for a shift towards personalized nutrition using cutting-edge technologies. From continuous glucose monitors to AI-powered apps and sensor to…
  continue reading
 
Alzheimer’s, Parkinson’s dementia, and other neurodegenerative diseases continue to be challenging, but now new science has led to a better understanding of the natural repair mechanisms in the brain. This, in turn, has generated new options for innovative treatments, and one such approach has entered late-stage human clinical trials. Dr. Mark Litt…
  continue reading
 
This week, Dr. Daniel Bloomfield from Anthos Therapeutics discusses the prevalence and dangers of blood clots, particularly in patients with cancer. Dr. Bloomfield explains the difference between normal and abnormal blood clotting, the risks associated with blood clots in arteries and veins, and the challenges in balancing clot prevention with the …
  continue reading
 
Amazon is a frequent visitor to the EU Parliament. In January alone, it had nine meetings with MEPs. But when it refused to appear before the Employment Committee on a hearing on crucial issues concerning working conditions within its warehouses, it made MEPs from all party groups extremelly angry, and rightly so. On 5 February, MEPs on the Europea…
  continue reading
 
Not just seeking treatment for every disease, but making sure the treatments we have already developed are being used in every possible way. I speak with Dr. David Fajgenbaum (Fay-gen-baum), a Professor of Translational Medicine and Human Genetics at the University of Pennsylvania School of Medicine, and President of Every Cure.…
  continue reading
 
When is a medical technology company more than a medical technology company? We’ll hear all about it when I speak with Dave Pacitti, the President and Head of the Americas at Siemens Healthineers. They’re out to solve problems bigger than the products they are known for.By Moira Gunn
  continue reading
 
Another year, another COP. As the UN climate talks concluded in Dubai, for the first time ever a “transition away from fossil fuels” has been mentioned in the final text, but calling for a win would be a clear overstatement. The text has the oily fingerprints of the fossil fuel lobby all over it. The reality is COP28 is more likely to facilitate a …
  continue reading
 
It's one year since the Qatargate corruption scandal exploded across the EU institutions and a good time to review if and how things have changed in the Brussels Bubble. In this episode, Joana Louçã talks to Corporate Europe Observatory's researchers Olivier Hoedeman and Vicky Cann.WHO WE AREThis podcast is produced by CEO and Counter Balance. Both…
  continue reading
 
This week we visit the brain, and look at what a flexible brain implant might do – from sensing how your brain is working to actual treatment. Nicolas Vachicouras from Neurosoft Bioelectronics in Geneva, Switzerland talks about the target for their first treatment: severe tinnitus.By Moira Gunn
  continue reading
 
What’s next after Ozempic and Wegovy and the like? How about a drug in development which releases all the relevant hormones, and not just GLP-1. And doesn’t require injecting. Dr. Steffen-Sebastian Bolz from Aphaia (ah-phi-ah) Pharma explains their approach, currently in Phase 2.By Moira Gunn
  continue reading
 
We honor Sir Ian Wilmut, the Scottish embryologist who gained worldwide renown as the leader of the scientific research group that cloned the equally famous Dolly. With his recent passing, we air our 2007 BioTech Nation interview, when David Ewing Duncan and I spoke with Dr. Wilmut on the 10th anniversary of Dolly’s birth.…
  continue reading
 
Dr. Mark Sumeray from Amolyt Pharma talks about their innovative approach to treating hormonal conditions. We’ll talk about two – when your parathyroid has been injured or removed, often during thyroid surgery, and another – when the pituitary starts overproducing growth hormone.By Moira Gunn
  continue reading
 
This week on BioTech Nation, Andrew Allen, President, CEO and Co-Founder of Gritstone Bio – a full spectrum look at how cancer starts and cancer treatments have developed … and what next-generation treatment means today with Gritstone’s work in colorectal cancer. And wait for it … the next generation of Covid vaccines.…
  continue reading
 
It’s the 25th anniversary of the founding of Google … and 23 years ago, Google founders - Larry Page and Sergey Brin – came to the Tech Nation studios to do their very first radio interview. There’s lots to learn there, including they believed what humans demanded of search, and why they did what they did.…
  continue reading
 
As the European Commission’s current mandate draws to a close, some Commissioner’s are contemplating their next moves. One such politician is current Vice President Margrethe Vestager, who is campaigning to become the next president of the European Investment Bank (EIB). She is one of five potential candidates who will take over from current EIB pr…
  continue reading
 
Loading …

Quick Reference Guide